Immune response to recombinant adenovirus in humans: Capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes

Journal of Virology

Volumn 74, Issue 16, 2000, Pages 7678-7682

  Molinier Frenkel, V ^a   Gahery Segard, H ^a   Mehtali, M ^a   Le Boulaire, C ^a   Ribault, S ^a   Boulanger, P ^a   Tursz, T ^a   Guillet, J ^a   Farace, F ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; DACTINOMYCIN; HLA ANTIGEN CLASS 1; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CAPSID; VIRUS RECOMBINANT;

ADENOVIRIDAE; CAPSID; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033865751     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.16.7678-7682.2000     Document Type: Article

References (34)

1. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors
2. Human CDS+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
3. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo
4. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
5. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: Comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy
6. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses
7. Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19K in the presence of gamma interferon
8. Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
9. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products
10. Recycling MHC class I molecules and endosomal peptide loading
11. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours
12. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
13. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver
14. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy
15. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted
16. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: Requirement for E4 ORF3
17. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
18. Introduction of soluble protein into the class I pathway of antigen processing and presentation
19. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells with human cytomegalovirus does not require endogenous viral gene expression
20. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
21. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
22. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
23. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro
24. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
25. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: Results of a phase 1 clinical trial
26. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
27. Phase I study of a recombinant adenoviral-mediated gene transfer in lung cancer patients
28. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
29. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
30. Cellular immunity to viral antigens limits E1 deleted adenoviruses for gene therapy
31. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs
32. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung
33. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes
34. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis